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Background: Heterozygous loss-of-function mutations in the X-linked CASK gene cause progressive microcephaly
with pontine and cerebellar hypoplasia (MICPCH) and severe intellectual disability (ID) in females. Different CASK
mutations have also been reported in males. The associated phenotypes range from nonsyndromic ID to Ohtahara
syndrome with cerebellar hypoplasia. However, the phenotypic spectrum in males has not been systematically
evaluated to date.
Methods: We identified a CASK alteration in 8 novel unrelated male patients by targeted Sanger sequencing, copy
number analysis (MLPA and/or FISH) and array CGH. CASK transcripts were investigated by RT-PCR followed by
sequencing. Immunoblotting was used to detect CASK protein in patient-derived cells. The clinical phenotype and
natural history of the 8 patients and 28 CASK-mutation positive males reported previously were reviewed and
correlated with available molecular data.
Results: CASK alterations include one nonsense mutation, one 5-bp deletion, one mutation of the start codon, and
five partial gene deletions and duplications; seven were de novo, including three somatic mosaicisms, and one was
familial. In three subjects, specific mRNA junction fragments indicated in tandem duplication of CASK exons
disrupting the integrity of the gene. The 5-bp deletion resulted in multiple aberrant CASK mRNAs. In fibroblasts from
patients with a CASK loss-of-function mutation, no CASK protein could be detected. Individuals who are mosaic for
a severe CASK mutation or carry a hypomorphic mutation still showed detectable amount of protein.
Conclusions: Based on eight novel patients and all CASK-mutation positive males reported previously three
phenotypic groups can be distinguished that represent a clinical continuum: (i) MICPCH with severe epileptic
encephalopathy caused by hemizygous loss-of-function mutations, (ii) MICPCH associated with inactivating
alterations in the mosaic state or a partly penetrant mutation, and (iii) syndromic/nonsyndromic mild to severe ID
with or without nystagmus caused by CASK missense and splice mutations that leave the CASK protein intact but
likely alter its function or reduce the amount of normal protein. Our findings facilitate focused testing of the CASK
gene and interpreting sequence variants identified by next-generation sequencing in cases with a phenotype
resembling either of the three groups.
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In 2008, we found the X-linked CASK gene (MIM
300172) to be mutated in female patients with a severe
neurodevelopmental disorder and distinct brain anomal-
ies which comprised progressive microcephaly, ponto-
cerebellar hypoplasia and severe developmental delay
(DD), named microcephaly with pontine and cerebellar
hypoplasia (MICPCH, MIM 300749) [1]. Subsequently,
the MICPCH phenotype has been well delineated by
several groups [2-5]. Affected females show primary or
rapidly postnatally evolving microcephaly, and typically
(moderate to) severe DD/intellectual disability (ID) with
no or very limited language. Facultative features are axial
hypotonia and/or peripheral hypertonia, movement and
behavioral disorders, and seizures [6]. These patients in-
consistently show short stature, various eye anomalies,
sensorineural hearing loss, and possibly a recognizable
facial phenotype, whereas congenital malformations are
rarely associated [2,4]. MRI findings are characteristic
and allow differentiation of other microcephalic disor-
ders, in particular of the different types of pontocerebel-
lar hypoplasia (PCH). In MICPCH, cerebellar hypoplasia
is diffuse affecting the hemispheres and vermis equally,
and pontine hypoplasia can show relative sparing of the
pontine bulging. Both pontine and cerebellar hypoplasia
can be mild to severe without correlation to the severity
of clinical manifestations [4,5]. The corpus callosum
(CC) is of normal or low-normal size, exhibits a low
cerebrum/CC ratio [7], and supratentorial anomalies are
subtle and non-specific possibly showing a rarefication
of gyri in the frontal region. Females with MICPCH
carry heterozygous loss-of-function mutations in CASK
including nonsense, frameshift, and splice site mutations
as well as partial or complete deletions/duplications of
CASK [1-5].
So far, only six males with likely loss-of-function alter-
ations of CASK have been reported [2,5,8,9], all present-
ing with a severe neurological phenotype except for one
who had a mosaic mutation. In addition, familial cases
of male patients with missense and splice mutations in
CASK have also been described. They exhibit mild to se-
vere ID with or without nystagmus or were diagnosed
with the so-called FG-syndrome [10-12]. It has been hy-
pothesized that CASK loss-of-function mutations are as-
sociated with reduced male viability or in utero lethality
[1], while hypomorphic mutations are associated with a
different phenotypic spectrum [10]. However, the pheno-
type in males associated with different CASK mutation
types has not been systematically evaluated.
We here report on eight unrelated male individuals,
seven sporadic and one familial case, with different
CASK alterations (nonsense and splice mutations, muta-
tion of the start codon, partial gene duplications and de-
letions, also in mosaic state), and evaluate the clinical,genetic and molecular data of these novel subjects and
the male individuals published previously. We also re-
view the current knowledge on pathogenic mechanisms
and genotype-phenotype correlation in individuals with
a CASK mutation.
Methods
Patients
Clinical and molecular findings in patients 1–8 as well
as in previously published male patients with a CASK al-
teration are summarized in Table 1. The clinical data
and samples were obtained with informed consent of the
patients’ parents/guardians, including consent to use the
photographs in this report, according to the Declaration
of Helsinki and the national legal regulations (e.g. Ger-
man Genetic Diagnosis Act [GenDG]).
Patient 1 was born in week 37 as the 1st child of
Dutch parents. He had primary microcephaly (−4.2 SD),
bilateral clubfeet which had already been noticed during
pregnancy, and craniofacial dysmorphism consisting of
dolichocephaly, puffy eyelids, broad nasal bridge, bulb-
ous tip of the nose, severe retromicrognathia, and ear
dysplasia with fleshy uplifted ear lobules (Figure 1).
Apgar scores were 3, 5 and 10 at 1, 5 and 10 minutes,
respectively. He had a severe neurologic disorder with
hypotonia, abnormal movements, inability to swallow
and intractable, probably myoclonic seizures. The EEG
was severely abnormal with multifocal abnormalities and
slow discontinued and flat episodes. On cranial MRI, severe
hypoplasia of medulla, pons and cerebellum, in particular
of cerebellar hemispheres, progressive cortical atrophy, sim-
plified gyri and hypomyelination were seen (Figure 2). Oph-
thalmologic examination revealed optic hypoplasia, BERA
severe sensorineural hearing loss, and cardiologic examin-
ation a large ASD I, a small ASD II, and atrioventricular
valve insufficiency 2/4. He suffered from severe apneas and
chronic hypoventilation for which he received CPAP and
caffeine. At age 7 months, he developed an airway infection
and died due to respiratory insufficiency despite antibiotic
treatment and respiratory support.
Patient 2 was the 7th child of an unrelated Pakistani
couple. The pregnancy was complicated by polyhydram-
nios, gestational diabetes controlled by a diet and IUGR.
He was born in week 37 with mild microcephaly (−2.5
SD), small for gestational age, and required cardiopul-
monary reanimation because of cyanosis and lack of
spontaneous breathing. He was severely hypotonic and
developed myoclonic seizures from his 1st month of life,
later tonic and infantile seizures which were difficult to
treat. His EEG showed a burst-suppression-pattern and
a probable diagnosis of Ohtahara syndrome was estab-
lished. Because of swallowing difficulties he was fed by a
PEG tube but continued to be dystrophic. He showed
nearly no development, and was last seen at the age of
Table 1 Male individuals with CASK mutations
Patient CASK mutation Birth OFC/W/L (SD) Age OFCa (SD) Heighta (SD) Weighta (SD) DD/ID Tonus
Pat 1 c.704_708del p.K236Efs*10 ex 7 dn w 37 +3 -4.2/-3.2/? † at 7 m −5.9 (4.5 m) −4.8 (6 m) −1 (6 m) profound, no development severe hypotonia
Pat 2 Dup ex 10–16 dn w 37 +3 -2.5/-1.9/
-1.5
10 m
† at 21 m
progressive microcephaly −2.4 −2.8 profound severe hypotonia
Pat 3 c.1A > G ex 1 dn −1.3/-0.3/? 5 y −5 (3 y) −3 −2 profound, no development severe hypotonia
−3.7 (5 y)
Pat 4 c.79C > T p.R27* ex 2 dn w 33 +2 -2.57/-1.14/
-1.73
15 m −9.0 −3.0 −1.67 profound severe hypotonia
Pat 5 Dup ex 4–20 mos w 36 +1 -1.8/0/0.3 7 m −7.8 (9 m) −2.1 (9 m) −0.6 (9 m) severe hypertonia
Pat 6 Del ex 1 mos −2.9/-1.1/-1.7 16 m −6 (11 m) −2 (11 m) −1.6 (11 m) severe hypertonia of limbs
Pat 7 Del ex 3–9 mos w 37–0.93/-0.5/-0.87 29 m −3.56 (29 m)
-2.55 (5;3 y)
−3.5 (29 m)
-2.42 (5;3 y)
−1.97 (29 m)
-1.45 (5;3 y)
severe tonus regulation disorder
Pat 8 Dup ex 1–5 mat −2 /0/-1.4 20 m −5 −2 −2 Mild to moderate DD
Pat 16b c.1061T > C p.L354Pc ex 12 5 y profound, no development
Pat 1e Del ex 2 matf −1.2/-2/-1.4 4 y −2.7 (1.4 y) profound
Pat 2e c.1A > G ex 1 dn −2.7/-3.3/-2.8 4 y severe hypertonia of limbs
Case reportg c.227_228del p.E76Vfs*6 ex 3 dn 0/0.1/1.4 8 m −5.4 severe hypotonia
Pat 13h c.278 + 1G > A in 3 dn −2/0/-0.5 16 m −6 −2 profound profound hypotonia
Pat 12h c.316C > T p.R106* ex 4 mos −3/-1.5/-2 15 y −3.5 −3.5 severe
Pat 5i c.915G > A p.(=) ex 9 dn † at 2 w microcephaly
Pat II 4j Fam V c.2183A > G p.Y728C ex 23 (2 ♂) 14 y −4.4k −2.9 thin severe
Pat II 2j 19 y −2.4k −1.7 thin moderate
Pat IV 1j,l Fam 74 c.2129A > G p.D710G ex 22 (4 ♂) 42 y normal normal mild
Pat III 3j,l 98th cen normal obese mild
Pat III 12j,l 98th cen normal obese mild
Pat III 6j,l 59 y normal normal mild
Pat IV 1j,l Fam 16 c.802T > C p.Y268H ex 8
(4 ♂, 1 without clinical description)
normal normal severe/profound
Pat III 4j,l severe
Pat II 3j,l severe
three Patj,l Fam 123 c.2756T > C p.W919R ex 27 (3 ♂) normal tall mild
Pat III 1j,l Fam 245 (K8919) c.1186C > T p.P396S ex 13
(4 ♂, 2 without clinical description)
58 y 0 short stature,
152 cm
profound
Pat III 4j,l 52 y 0 short stature,
147 cm
severe
Pat III 3j Fam 683 c.2521-2 A > T in 25 (4 ♂) 46 y +1.6 −2.2 mild
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Table 1 Male individuals with CASK mutations (Continued)
Patient CASK mutation Birth OFC/W/L (SD) Age OFCa (SD) Heighta (SD) Weighta (SD) DD/ID Tonus
Pat II 3j mild
Pat II 4j mild
Pat II 5j mild
Pat III 26m c.83G > T p.R28L ex 2 (3 ♂) 2 y relative macrocephaly 50-75th cen 25-50th cen marked hypotonia
Pat II 11m 34 y relative macrocephaly profound hypotonia in infancy
Pat II 17m 16 y short stature +, unspecified hypotonia in infancy
Patient Seizures EEG Other
neurologic
anomalies
Eye findings Sensorineural
hearing loss
Other anomalies Face MRI Overall
phenotype
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Table 1 Male individuals with CASK mutations (Continued)
Patient Seizures EEG Other
neurologic
anomalies
Eye findings Sensorineural
hearing loss
Other anomalies Face MRI Overall
phenotype
Pat 1 intractable seizures apnoeas, inability
to swallow
optic atrophy + ASD, bil. clubfeet dolichocephaly, puffy eyelids, broad nasal
bridge, bulbous tip of nose, severe
retromicrognathia, ear dysplasia, fleshy ear
lobes
severe hypo CBL + pons +
medulla, simplified gyri,
cortical atrophy
MICPCH
Severe
epilepsy
Pat 2 probably Ohtahara s.,
burst suppression
macropapilla, optic
atrophy?
+? long convex fingernails,
overriding 2nd toes, linear
blisters right leg, needed
PEG
retrognathia, fleshy uplifted ear lobules significant hypo CBL + pons MICPCH
Severe
epilepsy
Pat 3 intractable seizures opticus hypoplasia – AVSD, tapering fingers,
edema of the dorsum of
hands and feet, needed
PEG
long eyelashes, short nose, large ears with
fleshy uplifted ear lobules
small brain, hypo CBL + pons MICPCH
Severe
epilepsy
Pat 4 intractable seizures,
burst suppression
apnoea-
bradycardy-
syndrome,
inability to
swallow
optic atrophy? VSD, short limbs,
contractures of fingers
plagiocephaly, metopic ridge severe hypo CBL + pons,
progressive cortical atrophy,
progressive hypomyelination
MICPCH
Severe
epilepsy
Pat 5 spasms and
myoclonic seizures,
no hypsarrhythmia
– hyperopia ? micropenis, cryptorchidism sparse hair, broad nasal bridge, epicanthal
folds, long philtrum, retromicrognathia,
fleshy uplifted ear lobules
small brain, hypo CBL + pons MICPCH
epilepsy
Pat 6 – – hyperopia, strabism – cryptorchidism broad nasal bridge, epicanthal folds, long
philtrum, prominent premaxilla, mild
retrognathia, simple/thin auricle
hypo CBL + pons MICPCH
Pat 7 – mild ataxia – – – prominent nasal bridge, thin upper lip,
pointing chin
mild hypo CBL + pons
mildly simplified gyri
MICPCH
Pat 8 – – FTT long flat philtrum mildly smaller frontal lobes,
small CC (frontal), CBL and
otherwise normal
MIC + DD
Pat 16b West s., intractable
seizures
large eyes, large ears, broad nasal bridge,
broad nasal tip, epicanthal foldsd
MICPCH MICPCH
Severe
epilepsy
Pat 1e Ohtahara s. Long slender fingers,
micropenis, needed
tracheostomy + PEG
micrognathia, short neck severe hypo CBL, hypo ponsd MICPCH
Severe
epilepsy
Pat 2e Ohtahara s. PHPV – short upper arms,
overlapping fingers,
clinodactyly
micrognathia, high arched palate severe CBL hypo, hypo ponsd MICPCH
Severe
epilepsy
Case
reportg
early myoclonic
encephalopathy
(EME)
dystonia, chorea optic atrophy CP, tetralogy of Fallot, AMC,
hydronephrosis, VUR,
needed tracheostomy
micrognathia severe hypo CBL + pons MICPCH
Severe
epilepsy
Pat 13h intractable seizures,
spasms + tonic
seizures, suppression-
burst
spastic
tetraparesis,
dystonia
optic atrophy long slender fingers with
contractures, needed PEG
retrognathia, high arched palate, low-set
ears with prominent lobules, down-slanted
palpebral fissures, broad nasal bridge
very severe hypo CBL, hypo
pons
MICPCH
Severe
epilepsy
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Table 1 Male individuals with CASK mutations (Continued)
Patient Seizures EEG Other
neurologic
anomalies
Eye findings Sensorineural
hearing loss
Other anomalies Face MRI Overall
phenotype
Pat 12h – dystonia,
dyskinesia
– – well-arched eyebrows, broad nasal bridge,
hypertelorism?, anteverted nares, full lipsd
mild hypo CBL MICPCH
Pat 5i ? severe hypo CBL + pons, thin
and unmyelinated CC
MICPCH
Pat II 4j N, strabism, optic
atrophy
synophris, high nasal bridge, upslanted
palpebral fissures, short columellad
hypo CBL, pachygyria MICPCH +
N
Pat II 2j N, astigmatism similar to II 4 ND MIC +
Moderate
ID + N
Pat IV
1j,l
hand tremor N, strabism no dysmorphism ND Mild ID +
N
Pat III
3j,l
tremor, unsteady
gait
N, strabism ND Mild ID +
N
Pat III
12j,l
N normal Mild ID +
N
Pat III
6j,l
no dysmorphism ND Mild ID
Pat IV
1j,l
+ toe walker no N autistic no dysmorphism ND Severe ID
Pat III
4j,l
+ no N ND Severe ID
Pat II
3j,l
toe walker no N obsessive behaviour ND Severe ID
three
Patj,l
+, in one of three
patients at age 17 y
N no dysmorphism ND All 3: Mild
ID + N
Pat III
1j,l
tremor, unsteady
gait
flat mid face, open mouth, eversion of
lower lip
ND Severe IDS
Pat III
4j,l
strabism flat nasal bridge, anteverted nares, wide
mouth, broad palate, broad grooved
tongue, short broad neck
ND Severe IDS
Pat III
3j
+, absences – N, high myopia no dysmorphism ND Mild ID +
N
Pat II 3j + N, strabism, myopia,
astigmatism
ND Mild ID +
N
Pat II 4j – N, high myopia,
optic atrophy,
retinal pigment
anomalies
ND Mild ID +
N
Pat II 5j + N ND Mild ID +
N
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Table 1 Male individuals with CASK mutations (Continued)
Patient Seizures EEG Other
neurologic
anomalies
Eye findings Sensorineural
hearing loss
Other anomalies Face MRI Overall
phenotype
Pat III
26m
EEG mildly abnormal – + hyperactivity, aggressive
behaviour, constipation
prominent forehead, frontal upsweep,
hypertelorism, depressed nasal bridge, long
philtrum, micrognathiad
normal (on CT) IDS
Pat II
11m
+ aggressive behaviour,
constipation
prominent forehead, hypertelorism, broad
long philtrumd
ND IDS
Pat II
17m
+ hyperactivity, constipation,
cryptorchidism
prominent forehead, frontal upsweep, long
philtrum, epicanthal foldsd
ND IDS
Legends: The eight first listed patients (Pat 1-8 in bold) are described in detail in the manuscript, patients listed below have been reported previously. +, present; −, absent; †, died; AMC, arthrogryposis multiplex congenita; ASD, atrial
septal defect; AVSD, atrioventricular septal defect; bil., bilateral; CBL, cerebellum; CC, corpus callosum; cen, centile; CP, cleft palate; CT, computed tomography; DD, developmental delay; Del, deletion; dn, de novo; Dup, duplication;
EEG, electroencephalogram; ex: exon; F, female; Fam, family; FTT, failure to thrive; hypo, hypoplasia; ID, intellectual disability; IDS, syndromic intellectual disability; in, intron; L, length; m, months; mat, maternally inherited; MIC,
microcephaly; MICPCH, microcephaly with pontine and cerebellar hypoplasia; mos, somatic mosaicism; MRI, magnetic resonance imaging; N: nystagmus; ND, not documented; OD, right eye; OS, left eye; Pat, patient; PEG, percutane
g-tube; PHPV, persistent hyperplastic primary vitreous; s., syndrome; SD, standard deviation; VSD, ventricular septal defect; VUR, vesicoureteral reflux; W, weight; w, week of gestation; y, year(s).
aat last follow up (if not specified otherwise).
bTakanashi et al., 2012 [5].
cin original publication wrongly reported as p.L348P.
dbased on figures/photographs shown in publication.
eSaitsu et al., 2012 [9].
fthe mother is a somatic mosaic for the CASK mutation.
gJinnou et al., 2012 [18] and Nakamura et al., 2014 [8].
hBurglen et al., 2012 [2].
iNajm et al., 2008 [1].
jHackett et al., 2010 [10].
kin Table 1 of the original publication wrongly listed as normocephaly (absolute values were given in the text).
lTarpey et al., 2009 [12].
mPiluso et al., 2003 [19] and 2009 [11].
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Figure 1 Photographs of patients 1–8. Facial features of patients 1–8 are shown at the age of 1 day (patient 1), 9 months (patient 2, ear at 3
days), 19 months (patient 3), 7 months (patient 5), 16 months (patient 6), 5 years (patient 7), 14 months (patient 8), ears are depicted in the
bottom row. Apart from microcephaly, patients 5 and 6 show epicanthal folds and a long philtrum, patient 8 a flat smooth philtrum, patients
1, 5 and 6 a broad and patient 7 a prominent nasal bridge, patient 1 a bulbous tip of nose, patients 1 and 5 retromicrognathia, and patients 1, 2,
3 and 5 fleshy, uplifted ear lobules. There seems to be no recognizable facial phenotype.
Moog et al. Orphanet Journal of Rare Diseases  (2015) 10:44 Page 8 of 2010 months. Dysmorphic features consisted of retrognathia,
fleshy uplifted ear lobules, long convex fingernails, and
overriding 2nd toes (Figure 1). He died at the age of 21
months, probably from pneumonia. MRI brain showed
significant hypoplasia of the pons and all parts of the cere-
bellum. No supratentorial anomalies were seen except a re-
tardation of myelination (Figure 2).Figure 2 Selected axial, coronal and sagittal MR images from eight male in
show hypoplastic, flattened cerebellar hemispheres with proportionally red
row show intact corpus callosum in all cases, low forehead indicative for m
hypoplasia is severe in patients 1–5, moderate in patient 6, and mild in pat
number and complexity of the frontal gyri are seen in patients 1 and 7, an
imaging was performed at the age of 6 months (patient 1), 5 months (pati
11 months (patient 6), 10 months (patient 7), and 16 months (patient 8).Patient 3 was born as the 1st child of Dutch parents.
The pregnancy was established with IVF/ICSI with fro-
zen sperm which was obtained before the start of
chemotherapy because of a hematologic malignancy in
the father, and proceeded uneventfully. An ASD with bi-
cuspid aortic valve was diagnosed shortly after birth.
OFC at birth was within the normal range but rapidlydividuals with a CASK alteration. The coronal images (second row)
uced size of the vermis in patients 1–7. The sagittal images in the third
icrocephaly and pontine hypoplasia in patients 1–7. Pontocerebellar
ient 7. Cerebellum and pons of patient 8 are normal. A mildly reduced
d cortical atrophy in patients 1 and 4 (axial images in first row). MR
ent 2), 5 years (patient 3), 2 months (patient 4), 4 months (patient 5),
Moog et al. Orphanet Journal of Rare Diseases  (2015) 10:44 Page 9 of 20decreased to −2.5 SD at the age of 3 months and −5 SD
at age 3 years. He showed minor dysmorphic facial fea-
tures with fleshy earlobes (Figure 1). From the age of 2
weeks on epileptic attacks were noted. Despite antiepi-
leptic treatment he persisted having severe intractable
seizures. He was severely hypotonic and had feeding
problems, needing a PEG tube at age 2 years. He showed
virtually no motor or cognitive development. He was
able to recognize his parents in periods when his epi-
lepsy was more or less under control. He was last seen
when he was 5 years old and lived with his parents. He
was frequently hospitalized because of complications
related to his epilepsy. Ophthalmologic examination
showed optic hypoplasia and nearly no visual reactions
could be aroused. Cranial MRI showed significant hypo-
plasia of the pons and cerebellum (Figure 2).
Patient 4 was born as the 1st child of a German
couple in week 34 by Cesarean section following a preg-
nancy complicated by IUGR and preeclampsia/maternal
edema with primary microcephaly (−2.57 SD) and rele-
vant VSD. He suffered from respiratory and cardiac in-
sufficiency (apnoe-bradycardy-syndrome), showed severe
hypotonia from the beginning and was tube fed due to
inability to swallow. He developed different types of sei-
zures with burst suppression EEG from 2 months on.
On examination at 6 months of age, microcephaly corre-
sponded to −7.7 SD (corrected for prematurity), his skull
was asymmetric and had a metopic ridge. He showed
disproportionate short stature with a broad thorax, rhi-
zomelic shortening of limbs, and slender lower legs. He
had flexion contractures of fingers 2 and 4 on the left,
and 4 on the right side, a high palate, broad alveolar
ridges, mildly protruding ears of normal length with
overfolded helices (Figure 1), undescended testes, mild
shawl scrotum and a hemangioma on his back. At the
same age, he received surgery for inguinal hernia and a
PEG. At 15 months, he was still severely hypotonic and
showed little psychomotor development. His seizures
responded partly to levetiracetam and vigabatrin. Serial
MRI at the age of 2 and 10 months showed severe ponto-
cerebellar hypoplasia affecting particularly the cerebellar
hemispheres, progressive cerebral atrophy and progressive
hypomyelination (additional effects of complicated prema-
ture birth cannot be excluded) (Figure 2).
Patient 5 was one of dizygotic twins, born as the 1st
child in week 36 after a pregnancy established by egg cell
donation and ICSI, and complicated by maternal dia-
betes and polyhydramnios. Decelerated growth of head
circumference in fetus 1 was mentioned prenatally be-
ginning at 20 weeks of pregnancy. OFC at birth corre-
sponded to the 3rd centile. Patient 5 showed progressive
microcephaly up to −6.5 SD during the first half year of
life. He developed epileptic spasms at the age of 3
months but his EEG did not show hypsarrhythmia. Thetreatment could reduce the frequency of seizures. His
psychomotor development was moderately retarded at
the age of 6 weeks. Hearing impairment was suspected
but could not be validated. Myopia was diagnosed at 6
months. Examination at age 7 months revealed severe
global developmental delay with severe muscular hyper-
tonia and absence of social interaction, reflective smiling
or visual fixation. Dysmorphic signs comprised a broad
nasal bridge, epicanthal folds, a long philtrum, retromi-
crognathia, and fleshy uplifted ear lobules (Figure 1).
MR images showed a small brain with significant ponto-
cerebellar hypoplasia affecting the cerebellar vermis and
hemispheres equally (Figure 2).
Patient 6 was born at term following an uneventful
pregnancy as the 2nd child of an Iranian mother and a
German father with microcephaly (−2.9 SD). His mother
reported two previous miscarriages. He showed progres-
sive microcephaly during his 1st year of life and global
developmental delay from the beginning. At the age of
11 months, his motor development corresponded to 3
months and his Developmental Mental Index was < 50.
He had an afebrile seizure but otherwise normal EEG,
and his tonus was increased. He exhibited subtle facial
dysmorphism (broad nasal bridge, epicanthal folds, long
philtrum, prominent premaxilla, mild retrognathia, simple/
thin auricle, normal ear length) (Figure 1) reminiscent of
the facial phenotype described in CASK-mutation positive
females [4]. MRI of the brain showed moderate pontocere-
bellar hypoplasia affecting the cerebellar hemispheres and
vermis equally, but no further anomalies (Figure 2).
Patient 7 was born with a normal OFC as the 2nd
child of a nonconsanguineous German couple at 36 + 1
weeks of gestation. On examination at the age of 29
months, he showed microcephaly (−3.56 SD), short stat-
ure (−3.5 SD), global developmental delay, and a tonus
regulation disorder. Facial dysmorphism included a
prominent nasal bridge, thin upper lip, and a small
pointed chin (Figure 1). He walked at the age of 30
months and learnt some words, however, he could not
use them appropriately. At the age of 5;3 years, OFC
and height corresponded to −2.5 SD approximately, he
was able to run but fell frequently due to mild ataxia. He
was restless, constantly moving and reported to be nor-
motonic. He uttered sounds, no words and could not yet
be trained in sign language. His development had not
been tested formally. Brain MRI performed at 10 months
showed mild hypoplasia of the pons, cerebellar vermis
and hemispheres, and mildly simplified gyri (Figure 2).
Patient 8 was born at term to a 40-year-old Belgian
mother. OFC corresponded to −2 SD at birth. He
showed failure to thrive, rapidly progressive secondary
microcephaly up to −5 SD at age 20 months, and mild
to moderate developmental delay without further neuro-
logic signs. The only physical anomaly consisted of a flat
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months showed mildly smaller frontal lobes and a small
frontal part of the corpus callosum. Cerebellum and
pons were normal (Figure 2). The mother of patient 8
had a history of special education for learning difficul-
ties, her OFC being 53 cm (3rd centile). She had three
girls and a boy from a previous marriage, two of the girls
required special education; the boy and a full sister of
patient 8 were healthy.
Molecular karyotyping
DNA was isolated from leukocytes, lymphoblastoid, fibro-
blast and buccal cells by standard procedures. Copy
number profiling for patient 7 was performed using the
SurePrint G3 Custom CGH Microarray, 4x180K (G4125A,
Agilent Technologies, Santa Clara, CA, USA), a high reso-
lution 60-mer oligonucleotide based microarray with me-
dian overall probe spacing of about 13 kb. Labelling and
hybridization of genomic DNA were performed according
to the protocol provided by Agilent without enzymatic re-
striction. Data visualization and analysis was performed as
described [13]. Copy number profiling for patient 8 was
performed on a 60K oligonucleotide array (Agilent Tech-
nologies, Diegem, Belgium) according to the manufacturer’s
instructions with minor modifications as described [14].
CNV evaluation was performed using the in-house devel-
oped software tool arrayCGHbase [15].
Multiplex ligation-dependent probe amplification (MLPA)
SALSA MLPA P398 CASK probemix (version A1)
(MRC-Holland, Amsterdam, The Netherlands) was used
according to the manufacturer’s instructions to detect sin-
gle and multiple exon deletions/duplications in the CASK
gene (exons 1–23 and 25–27). MLPA results were analysed
with the Sequence Pilot algorithm, version 4.0.1 (JSI Med-
ical Systems, Kippenheim, Germany). A relative probe sig-
nal of 1 (100%) in a male sample DNA reflected one copy
of target sequence of the CASK-specific probe. Mosaic dele-
tions of a probe’s recognition sequence led to a significant
reduction in relative peak area (by 35-50% or higher). Rela-
tive signals of 1.5 (150%) of CASK-specific probes indicated
two copies of the respective target sequences.
Sequencing of CASK
The coding region of the CASK gene (27 exons) [Gen-
Bank:NM_003688] was amplified from genomic DNA.
Primer sequences are available on request. Amplicons
were directly sequenced using the ABI BigDye Termin-
ator Sequencing Kit (Applied Biosystems, Darmstadt,
Germany) and an automated capillary sequencer (ABI
3500; Applied Biosystems). Sequence electropherograms
were analysed using Sequence Pilot software (JSI Medical
Systems).Fluorescence in situ hybridization (FISH)
Metaphase spreads from peripheral blood lymphocytes
were prepared by standard procedure and counterstained
using 4′,6-diamidino-2-phenylindole (DAPI). BAC (RP11
human BAC library) and fosmid clones (WIBR-2 human
fosmid library [G248P8]) were received from the BACPAC
Resource Center, Children’s Hospital Oakland, CA, USA.
BAC and fosmid DNA preparation and labelling as well as
fluorescence microscopy and analysis of images was per-
formed as previously described [16].Cell culture
Fibroblast cells were cultured in Dulbecco’s modified
Eagle medium (DMEM; Life Technologies, Darmstadt,
Germany) and lymphoblastoid cell lines in Roswell
Park Memorial Institute 1640 medium (RPMI 1640; Life
Technologies), both supplemented with 10% (v/v) fetal
bovine serum (FBS; PAA Laboratories, Cölbe, Germany)
and penicillin-streptomycin (100 U/ml and 100 μg/ml,
respectively; Life Technologies) and incubated at 37°C in
a humidified atmosphere with 5% CO2.Transcript analysis and cloning
Total RNA of patient 5 and three healthy males was ex-
tracted by using the PAXgene Blood RNA Kit (PreAn-
alytiX/QIAGEN, Hilden, Germany) according to the
manufacturer’s instructions. Total RNA was extracted
from cultured primary fibroblasts of patients 1, 2 and 5
and three healthy individuals as well as from lympho-
blastoid cells of patient 8 and one healthy individual
(RNeasy Mini Kit, QIAGEN). 1 μg of RNA was reverse
transcribed into cDNA (Superscript II®; Invitrogen,
Karlsruhe, Germany) using random hexanucleotides
(Invitrogen) according to the manufacturer’s protocol. RT-
PCR fragments were obtained by using different primer
combinations according to standard PCR protocols (see on-
line Additional file 1: Table S1). PCR products were cloned
into pCR2.1 TOPO TA Cloning® Vector (Invitrogen). E.coli
clones were subjected to colony PCR and PCR products
from individual clones were sequenced.Antibodies and reagents
The following primary antibodies and dilutions were used:
rabbit anti-CASK antibody (named anti-CASK2 antibody;
WB 1:500; Cell Signaling Technology, Danvers, MA, USA),
mouse anti-CASK antibody (named anti-CASK1 antibody;
WB 1:1000; Millipore, Schwalbach, Germany), mouse anti-
α-tubulin antibody (clone DM 1A; WB 1:7500; Sigma-
Aldrich, Taufkirchen, Germany). As secondary antibodies,
horseradish peroxidase-conjugated anti-mouse and anti-
rabbit antibodies (1:1000–1:10000 dilution; GE Healthcare,
Munich, Germany) were used.
Figure 3 (See legend on next page.)
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Figure 3 Partial CASK deletions and duplications. A. MLPA results on DNA isolated from leukocytes of patients 2, 5, 6, and 7 and on lymphoblastoid
cell-derived DNA of patient 8. Bars in upper and lower histograms represent MLPA probes. Peak area histogram (upper histogram): blue bars represent the
mean probe signals with standard deviations for three reference DNAs, except for patient 7 (one reference DNA); green bars: probe signals for patient
DNA. Numbers below the bars indicate the amplicon size (bp) of each MLPA probe. Lower histogram: the bar for each probe represents the probe signal
for patient DNA as percentage of the mean signal for the reference DNAs. Light blue bars represent percentages ranging from 75 to 125% (red dotted
lines); deviations lower and higher than 75 and 125% are represented by dark blue bars. Deleted/duplicated CASK exons are indicated below the dark blue
bars. B. Ideogram of the X chromosome is shown on the top. The Xp11.4 and the Xq25 regions are indicated by a red and a green bar, respectively. The
CASK exon-intron structure is enlarged below: vertical lines represent exons and horizontal lines introns; selected exons are numbered. The two fosmid
clones used to confirm somatic mosaicism of the CASK exon 3–9 deletion in patient 7 are indicated by red bars and names are given. BAC RP11-103K12
(Xq25) (indicated below the ideogram) was used as control probe. C. FISH with fosmid G248P83076E8 on a metaphase spread of patient 7 revealed a
signal (red) on the wild-type (WT) X chromosome (arrow pointing to the normal X in the right picture), while the same probe did not hybridize on the
X chromosome in another metaphase (arrow pointing to the del(X) in the left picture; see online Additional file 1: Table S1). RP11-103K12 gave a green
signal in both metaphases.
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Cells were washed with ice-cold 1x PBS and harvested
in modified RIPA buffer (150 mM NaCl, 50 mM
Tris–HCl, pH 8.0, 0.5% sodium desoxycholate [w/v],
1% Nonidet P40 [v/v], 0.1% sodium dodecyl sulfate
[w/v]) containing protease inhibitor cocktail (Roche,
Mannheim, Germany). Cell debris was removed by
centrifugation at 14000 rpm for 10 minutes at 4°C and
protein solutions were supplemented with sample buf-
fer. Proteins were separated on SDS-polyacrylamide
gels and transferred to PVDF membranes. Following
blocking (20 mM Tris–HCl, pH 7.4; 150 mM NaCl;
0.1% Tween-20; 4% non-fat dry milk) and washing
(20 mM Tris–HCl, pH 7.4; 150 mM NaCl; 0.1% Tween-
20), membranes were incubated in primary antibody
solution (20 mM Tris–HCl, pH 7.4; 150 mM NaCl;
0.1% Tween-20; 5% BSA or 0.5% non-fat dry milk)
containing the appropriate antibody. Next, membranes
were washed and incubated with the peroxidase-
coupled secondary antibody. After final washing,
immunoreactive proteins were visualized using the
Immobilon Western Chemiluminescent HRP Substrate
(Millipore).Results
CASK mutations
High resolution molecular karyotyping was performed on
a clinical basis on patients 7 and 8 and revealed copy
number changes in Xp11.4: a possible mosaic deletion
of ~160 kb (chrX: 41,496,539-41,655,017; hg19) in indi-
vidual 7 (Additional file 1: Figure S1) and a duplication
of 450–600 kb (chrX: 41,531,408-41,987,619; hg18) in
patient 8 (Additional file 1: Figure S2). Both alterations
cover part of the CASK gene, however, the duplication
also encompassed a gene desert region of ~300 kb
upstream of CASK (Additional file 1: Figure S2). We
further characterized the two alterations by multiplex
ligation-dependent probe amplification (MLPA). We con-
firmed the duplication of CASK exons 1–5 in DNA isolatedfrom lymphoblastoid cells of patient 8 (Figure 3A) and
identified his mother as carrier of the partial CASK duplica-
tion (data not shown). All three half sisters of individual 8
(including two half sisters with learning disabilities) did not
carry the duplication as shown by molecular karyotyping;
the half brother and full sister could not be tested. In
patient 7, the mosaic deletion covering CASK exons 3–9 in
DNA isolated from leukocytes and buccal cells was
confirmed as the dosage of the seven exons was reduced by
50-60% compared to the other exons (Figure 3A and data
not shown). FISH with the two fosmid clones
G248P80427H9 and G248P83076E8 (Xp11.4) and BAC
RP11-103K12 (Xq25) as control probe on metaphase
spreads of patient 7 revealed that the CASK microdeletion
was present in ~34% (22/65) of his leukocytes (Figures 3B
and C and Additional file 1: Figure S2).
Sequence analysis of the 27 coding exons of CASK was
performed on six male patients and revealed three
pathogenic mutations: the nonsense mutation c.79C > T
(p.R27*) in patient 4, the 5-bp deletion c.704_708delA-
TAAG in patient 1 and a transition affecting the start
codon, c.1A > G, in patient 3 (Table 1). The A-to-G
change of the first ATG codon has previously been re-
ported in a male with Ohtahara syndrome and cerebellar
hypoplasia [9]. These three hemizygous CASK alter-
ations were not present in the mothers of the patients
and therefore occurred de novo.
MLPA for the CASK gene on the remaining three pa-
tients identified two intragenic duplications, one of exons
10–16 in patient 2 (Figure 3A) and one of exons 4–20 in
patient 5 (Figure 3A). In patient 6, the relative peak area
of the two probes for exon 1 was reduced by 50-60% indi-
cating a mosaic deletion of this CASK exon (Figure 3A).
Somatic mosaicism of the exon 1 deletion was confirmed
in buccal cell-derived DNA of patient 6 by MLPA as the
dosage of this exon was reduced by ~60% (data not
shown). The two duplications were also detected in DNA
isolated from the patients’ fibroblasts as well as in a third
tissue (buccal cells) of individual 5 (data not shown). The
mother of patient 2 did not carry the exon 10–16
Figure 4 (See legend on next page.)
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Figure 4 Transcript analysis of the CASK gene. A, B, C and D. Schematic representation of CASK transcript variants and representative RT-PCR
products in patients 1, 2, 5 and 8. CASK exons are indicated by boxes: green boxes represent the coding region, blue boxes duplicated coding
exons and the light grey box the 5′ untranslated region in exon 1. Primers used for RT-PCR experiments are represented by yellow (forward
primer) and red (reverse primer) arrows (see online Additional file 1: Table S1). Premature termination codons are indicated by red stars above the
respective transcript variant. CASK transcript analysis was performed using (A) lymphoblastoid cell-derived RNA of patient 8, (B) fibroblast-derived
RNA of patient 2 (P2) and three healthy individuals (C2-C4), (C) leukocyte- and fibroblast-derived RNA of patient 5 (P5) and two healthy individuals
(C1, C2) and (D) fibroblast-derived RNA of patient 1 (P1) and one healthy individual (C2). RT-PCR products are shown on the right for patients
1, 2 and 5 and healthy individuals as controls. C. A CASK fusion transcript was amplified from RNA isolated from both leukocytes and fibroblasts
of patient 5 (left representative agarose gel electrophoresis picture), while a band corresponding to CASK wild-type transcript (from exon 3 to 21)
was only generated from fibroblast-derived RNA of the patient (right representative agarose gel electrophoresis picture). A water control (H2O)
was used in each RT-PCR reaction. The bright 600 bp reference band of the 100 bp DNA ladder and the 1636 bp band of the 1 kb DNA ladder
are indicated by an arrow. del, deletion; nt, nucleotides; bp, base pairs.
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of patient 5 was not available.
CASK transcript analysis
To analyse if the duplicated CASK exons (1–5, 4–20 and
10–16) in patients 8, 5 and 2 were arranged in tandem
and disrupt the integrity of the gene, we performed RT-
PCR analysis to characterize CASK transcripts in the
three patients. In patient 8 with the exon 1–5 duplica-
tion, we identified four different aberrant mRNAs in
which exon 5 was directly spliced to exon 2, exon 3 or
exon 4, and the fourth transcript contained exon 5, part
of intron 5, and exons 1–4 indicating an in tandem du-
plication (Figure 4A). All these CASK transcripts har-
boured a premature termination codon (Figure 4A). We
also amplified a CASK mRNA variant consisting of
exons 1–6 and harbouring the 5′ untranslated region
and start codon (Figure 4A). This mRNA could lead to
the production of normal CASK protein.
In individuals 2 and 5, we amplified specific mRNA
junction fragments that were not obtained in healthy in-
dividuals indicating an intragenic in tandem duplication
(Figure 4B and C). Sequencing of the aberrant CASK
transcript in patient 2, who carried the exon 10–16
duplication, revealed that exon 16 was spliced to exon
10, followed by exons 12 and 13. This out-of-frame
CASK transcript was found in both RNA isolated from
leukocytes and fibroblasts and contained a premature
termination codon in exon 10 (Figure 4B). Cloning and
sequencing of the junction fragments obtained from
leukocyte- and fibroblast-derived RNA of patient 5 de-
tected aberrant splicing of exon 17 or exon 18 to exons
4 and 5 indicating that exons 19 and 20 were skipped in
the majority of transcripts, and exons 18–20 in some of
them (Figure 4C). Both CASK transcript variants (exon
17-4-5 and exon 18-4-5) contained a premature stop
codon in exon 4 (Figure 4C).
The 5-bp deletion c.704_708delATAAG in patient 1
leads to a frameshift and introduction of a premature ter-
mination codon (p.(K236Efs*10)). However, this deletion af-
fects the last five nucleotides of exon 7 suggesting thatrecognition of the adjacent splice donor site in the
pre-mRNA could be disturbed by the spliceosome. We
tested this hypothesis by performing RT-PCR on RNA
isolated from fibroblasts of patient 1 that yielded mul-
tiple amplicons of different sizes compared with a
single PCR product generated from control RNA
(Figure 4D). Amplicon cloning followed by sequencing
of a total of 53 clones revealed five different CASK
transcript variants in fibroblasts of patient 1: in the
major transcript form exon 7 was skipped; minor
forms included transcripts containing exons 5 to 8
with the 5-bp deletion in exon 7, transcripts lacking
both exons 7 and 8 as well as transcripts with a short-
ened exon 7 (skipping of 39 bp or of 97 bp at the 3′
end) (Figure 4D and Additional file 1: Figure S3).
Three out of the five CASK mRNA variants harboured
a premature termination codon in exon 8 (Figure 4D).
CASK protein analysis
To analyse if the male patients with a CASK mutation
express normal and/or a truncated protein variant, we
performed immunoblot analysis with protein lysates pre-
pared from lymphoblastoid cells of patient 8 and fibro-
blasts of individuals 1, 2 and 5. No cell line was available
for the other four patients. We initially used an anti-
CASK antibody which detected the CASK-specific do-
main from amino acids 318–415 (named anti-CASK1
antibody; Figure 5A). In lymphoblastoid cells of patient
8, we observed a faint band with a molecular weight
of ~110 kDa corresponding to wild-type protein
(Figure 5B). However, the amount of CASK was drastic-
ally decreased in patient 8 compared with two healthy
individuals (Figure 5B). In fibroblast cells of patient 2
with the CASK exon 10–16 duplication and of patient 1
with the splice mutation c.704_708delATAAG, no CASK
protein could be detected, while a prominent band cor-
responding to CASK wildtype was visible in two fibro-
blast cell lines of healthy individuals (Figure 5C). In
contrast, a faint band with the expected molecular
weight of wild-type CASK (~110 kDa) was observed in
the fibroblast lysate of patient 5 (Figure 5C). To confirm
Figure 5 Expression of CASK protein. A. Domain structure of the longest CASK isoform [GenBank:NP_003679.2]. Domains are represented by
boxes in black and different shades of grey. The number on the left and right indicates the first and last amino acid residue of this CASK isoform,
respectively. Black bars below the domain structure show the two regions used as immunogen to produce anti-CASK1 and anti-CASK2 antibodies.
CaMK: calmodulin-dependent kinase-like domain; L27: LIN-2 and LIN-7 interaction; PDZ: PSD-95-Dlg-ZO1; SH3: Src homologous 3; 4.1: protein 4.1
interaction; GK: guanylate kinase. B. Total cell lysates of lymphoblastoid cells derived from patient 8 (P8) and two healthy male individuals
(C5 and C6) were subjected to SDS-PAGE and immunoblotting. The amount of total CASK protein was monitored by using the anti-CASK1
antibody (Millipore) (upper panel). Anti-α-tubulin antibody was used to control for equal loading (lower panel). C. Total fibroblast cell lysates
from patients 1, 2 and 5 (P1, P2 and P5) and two healthy male individuals (C3 and C4) were analysed by immunoblotting using the anti-CASK1
antibody (Millipore) (middle panel) and the anti-CASK2 antibody (Cell Signaling) (upper panel). Equal loading was controlled by an anti-α-tubulin
antibody (lower panel).
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of the three patients 1, 2 and 5 as well as of two healthy
males with another anti-CASK antibody, recognizing
residues surrounding threonine 774 (COOH terminus)
(anti-CASK2 antibody; Figure 5A). Similar to the anti-
CASK1 antibody, this antibody also identified a small
amount of wild-type CASK protein in the fibroblast lys-
ate of individual 5 (Figure 5C), suggesting that fibroblast
cells of this patient still generate some wild-type CASK
transcripts that are translated to produce normal pro-
tein. These data indicate that patient 5 is a somatic mo-
saic for the intragenic CASK exon 4–20 duplication, but
with a high level mosaicism. We confirmed somatic mo-
saicism for this CASK alteration by amplification of a
wild-type CASK transcript comprising the coding regionof exons 3–21 (1700 bp) in fibroblast-derived RNA of pa-
tient 5, while no such amplicon could be generated from
RNA isolated from his leukocytes (Figure 4C).Discussion
We present eight new, unrelated male patients with a
CASK alteration and a detailed characterization of their
clinical features, genetic and molecular data. Based on
our findings and previously published results on
sporadic and familial cases (Table 1), we propose the ex-
istence of three phenotypic groups in males (Figure 6)
which can be clinically distinguished but represent a
clinical continuum from the severe to the mild end of
the spectrum.
Figure 6 Summary of CASK mutations in males. Exons of CASK are represented as light brown boxes and introns as black bars. The exon-intron
structure is not drawn to scale. CASK mutations are given at the nucleotide level (for variants affecting splicing and for variants for which the prediction
on protein level is not possible) or protein level. The arrows point to the position of the mutation within the exon or intron. Duplications of CASK exons
are represented by grey bars and deletions by black bars; dots indicate that the exact duplication/deletion breakpoints have not been determined.
Mutations associated with microcephaly and pontocerebellar hypoplasia (MICPCH) with/without epilepsy are grouped above the exon-intron structure
(yellow background); mutations in individuals with severe MICPCH with epilepsy and less severe MICPCH are differentiated by dark and light yellow
background, respectively. Mutations in males with X-linked intellectual disability (XLID) are shown below the exon-intron structure (light grey back-
ground), those associated with nystagmus have a dark grey background. The yellow framed p.Y728C change was identified in two brothers, one with
MICPCH and nystagmus and one with ID, microcephaly and nystagmus. P1-P8: Numbering of patients 1–8 as described in this study.
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epileptic encephalopathy:
This group includes ten individuals so far (patients
1–5 reported here and five patients reported
previously, Table 1). CASK alterations in these
patients likely represent germline mutations, except
for patient 5, and include a missense mutation, a
nonsense mutation, a splice site mutation, a
mutation affecting the start codon in two
individuals, a 2 bp and a 5 bp deletion, two
intragenic duplications of multiple exons and a
deletion of exon 2 (this report and refs. [2,5,8,9]).
Transcript analysis in our patients 1, 2 and 5 and
the patient with the exon 2 deletion revealed that
the mutations severely disturb the integrity of the
CASK gene as aberrant mRNAs with a premature
termination codon were produced (this report and
ref. [9]). In addition, wild-type CASK protein was
absent in cells of patients 1 and 2 (this report) and
the two patients with c.1A >G and the exon 2
deletion [9], further indicating that these males carry a
CASK null allele. Patient 5 also has an inactivating
CASK mutation, however, by immunoblotting we
demonstrated a small amount of CASK protein with amolecular mass corresponding to that of wildtype in
his fibroblasts. To confirm expression of wild-type
CASK, we tried to amplify a CASK transcript harboring
exons 3–21 from RNA isolated from leukocytes and
fibroblasts of patient 5 and indeed generated an
RT-PCR product from his fibroblast-derived RNA. This
finding indicates that patient 5 has a high level somatic
mosaicism of the exon 4–20 duplication. In accordance
with this interpretation, no exon 3-to-21 transcript
was amplified from leukocyte-derived RNA of patient 5
suggesting that expression of CASK is generally low in
blood and/or the degree of somatic mosaicism of the
exon 4–20 duplication is higher in leukocytes than in
fibroblasts.
In this group, the affected males have the most
severe clinical presentation. Developmental delay is
severe to profound; the eldest reported patients are
5 years of age and hardly show any development
(patient 3 in Table 1 and patient 16 in ref. [5]).
Similar to females with MICPCH, microcephaly is
congenital or evolves rapidly during the first months
of life and later becomes significant (up to −9 SD).
MRI consistently shows significant or severe
pontocerebellar hypoplasia. Other brain
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(progressive) cortical atrophy and progressive
hypomyelination but no further supratentorial
involvement. Seizures manifest as Ohtahara
syndrome, West syndrome, early myoclonic
encephalopathy or just as unspecified intractable
seizures. We conclude that CASK loss-of-function
alterations cause severe epileptic encephalopathy in
males but do not specifically underlie e.g. Ohtahara
syndrome. Affected individuals frequently need a
percutaneous endoscopic gastrostomy (PEG) for
feeding and/or tracheostomy because of apnea.
Congenital heart defects, in particular septal defects,
are present in 4/10 patients and contractures, long
slender fingers or shortening of limbs in two. 8 of 10
show retro-/micrognathia and fleshy uplifted ear
lobules are seen in five patients (Figure 1).
Male individuals with a severe CASK mutation
clinically manifest with unspecific early epileptic
encephalopathy and congenital or early postnatal
and rapidly progressing microcephaly. Thus, the
brain imaging findings are the major diagnostic clue
and should prompt CASK testing, however, the
differential diagnosis of other pontocerebellar
hypoplasia (PCH) forms can be challenging [17].
For example, the CASK-mutation positive patient
reported by Nakamura et al. [8] had been previously
described with a clinical diagnosis of PCH type 3
[18], and it cannot be excluded that additional
individuals with PCH may have been misclassified
and are without a molecular diagnosis up to date.
(ii) MICPCH and a severe developmental disorder but
without severe epilepsy:
The CASK alterations in this group of five individuals
(patients 6–7 reported here and three patients reported
previously, Table 1) include severe mutations in mosaic
state (nonsense mutation, exon 1 deletion and exon
3–9 deletion) as well as a partly penetrant splice
mutation (c.915G >A, affecting the last nucleotide of
exon 9) and a missense mutation (c.2183A >G,
p.Y728C), both in the hemizygous state (this report
and refs. [1,2,10]). The three patients with somatic
mosaicism of the CASK mutation produce wild-type
protein in a significant percentage of their cells, most
likely reducing clinical severity in these cases.
The phenotype of the males in this group is
comparable to MICPCH in females. DD/ID (if
specified) is severe, microcephaly is variable and the
degree of pontocerebellar hypoplasia on MRI does
not necessarily correlate with the degree of DD.
Seizures have not been described in the five
individuals, however, patient 5 reported in Najm
et al. [1] deceased shortly after birth. The
interpretation of clinical data of this patient group islimited by the small sample size and restricted data
on patient 5 [1]. One individual, patient II-4 of
family V in Hackett et al. [10], presented with
nystagmus besides severe ID and cerebellar hypoplasia.
His brother (patient II-2) shows a similar but milder
phenotype, with nystagmus and mild microcephaly but
no imaging of the brain has been reported.
(iii)mild to severe ID with or without nystagmus:
The 21 cases of this group (patient 8 reported here
and 20 cases published previously) are all familial
and carry splice mutations or missense variants
affecting amino acid residues in different CASK
protein domains (Figure 6) [10-12]. Patient 8
harbors a duplication of exon 1 to 5 which was
inherited from his mother. We identified multiple
aberrant CASK transcripts in lymphoblastoid cells of
this individual, however, we also amplified a CASK
mRNA which contained exons 1 to 6 in the correct
order, including part of the 5' untranslated region.
Consistently, we detected a small amount of
wild-type CASK protein in the patient’s cells
indicating that some CASK transcripts are
efficiently translated.
In this group, microcephaly is documented only in
individual 8 and in patient II.2 of family V [10].
Pontocerebellar hypoplasia or other brain anomalies
can only be excluded in a minority of patients
because imaging of the brain has often not been
performed or reported. Various seizure disorders
have been reported for seven males from four
families, in none of them being severe. Nystagmus
was observed in 12 patients. Short stature, facial
dysmorphism, behavioural problems, tremor and/or
hypotonia may be associated. Intrafamilial variability
seems to be small, in particular with regard to eye
findings and the degree of ID. In the family with
the segregating c.83G > T mutation, the affected
males have been described as having FG syndrome
(FGS) [11,19], which is a heterogeneous X-linked
condition initially described by Opitz and Kaveggia
(Opitz-Kaveggia syndrome, MIM 305450) [20]. FGS1 is
caused by a recurrent mutation inMED12 (MIM
300188) [21], and has a well-defined phenotype
consisting of DD/ID, hypotonia, dolichomacrocephaly,
characteristic facies including small ears and
hypertelorism, and congenital anomalies of the corpus
callosum, heart and/or skeleton. The phenotype of the
other FGS types, however, is poorly defined. Thus, we
propose the clinical diagnosis of the males with the
CASK mutation c.83G >T should be syndromic ID
rather than FGS.
Restricted clinical data are available for 13 carrier
females from seven families. No abnormalities are
reported in seven of these females, deriving from
Moog et al. Orphanet Journal of Rare Diseases  (2015) 10:44 Page 18 of 20three families. Four carriers showed mild to severe
ID, one had absence seizures, two tremor, and three
nystagmus. MRI findings are given for one carrier
only (no anomalies) who presented with ID and
nystagmus.The three phenotypic groups, however, represent a
clinical continuum and at least two males link the
groups: patient 5 with a high level mosaicism for the du-
plication of exons 4 to 20 and a less severe form of epi-
lepsy links group I to II; and patient II.4 from family V
with the missense mutation c.2183A > G (p.Y728C) [10],
who represents the interface to group (iii) as he and his
brother who carried the same mutation both had
nystagmus.
CASK encodes the calcium/calmodulin (CaM)-
dependent serine protein kinase which belongs to the
membrane-associated guanylate kinase (MAGUK) pro-
tein family, the most prominent family of multidomain
scaffolding proteins [22]. CASK has been shown to con-
trol synapse formation and activity by (i) presynaptic
organization and regulation of neurotransmitter release,
(ii) maintaining the morphology of dendritic spines and
trafficking of ion channels to the postsynaptic site, and (iii)
regulating the transcription of genes involved in cortical de-
velopment by entering the nucleus [23,24]. However, the
exact pathomechanism underlying the clinical spectrum
ranging from MICPCH with severe epilepsy to mild ID is
still unclear. In general, hemizygous CASK variants in males
of phenotype group (iii) have been suggested to represent
hypomorphic alleles [10,11], altering one or more of the
multiple CASK functions while preserving others. An
impact on protein structure and/or function has been
demonstrated for the pathogenic CASK alterations
p.Y728C and p.W919R, while the nature of the deleterious
impact on CASK function remains to be determined for
p.R28L, p.Y268H and p.P396S [25,26]. The two splice mu-
tations c.2129A >G and c.2521-2A >T likely lead to the
production of CASK proteins lacking several amino acid
residues [10,11]. These mutant proteins may misfold, mislo-
calize, loose their capacity to bind CASK interaction part-
ners and/or have a changed function. For example, the
constitutively active CaM-kinase domain in the N-terminus
of CASK [27] could be affected by the amino acid alteration
p.R28L.
The nature of the CASK mutations found in males of
phenotypic groups (i) and (ii) is quite different from that
of group (iii) and corresponds to the mutation types
found in females [2-5]. Indeed, germline and mosaic al-
terations consistently found in group (i) likely are null
alleles as has been shown by CASK transcript analysis
and immunoblotting demonstrating the absence of
CASK protein in different cell types of severely affected
individuals (Figures 4 and 5; ref. [9]). The non-synonymous CASK mutation c.1061T > C/p.L354P found
in a 5-year-old male patient of this group is possibly a
loss-of-function mutation in view of his severe pheno-
type, but the functional consequences of this alteration
have not been investigated [5]. The small amount of nor-
mal CASK protein in patient 5 correlated well with the
presence of CASK wild-type transcript in his fibroblasts
(Figure 4C). Somatic mosaicism for a severe CASK mu-
tation attenuates the phenotype in males, as shown for
patients 6 and 7 in our cohort and patient 12 described
by Burglen et al. [2]. However, the level of somatic mo-
saicism can be high, as in patient 5, and may mimic a
germline mutation. Patients who are somatic mosaics of
a CASK inactivating mutation are expected to produce
wild-type CASK protein in a small percentage of their
cells, as demonstrated for patient 5. Obviously, this sce-
nario did not protect them from developing pontocere-
bellar hypoplasia that can readily be detected on brain
imaging. Interestingly, in lymphoblastoid cells of patient
8 who carried the CASK exon 1–5 duplication, a small
amount of wild-type CASK protein was observed. How-
ever, in contrast to somatic mosaics, this patient still
produces some wild-type CASK in all of his cells and
not only in a portion of cells. It can be hypothesized
that the small amount of functional CASK was suffi-
cient for an apparently normal structural development
of the brain in patient 8, but led to microcephaly and
ID, similar to the missense and splicing mutations de-
scribed in males with X-linked non-syndromic/syn-
dromic ID.Conclusions
In summary, we describe three phenotypic groups
forming an overlapping spectrum of CASK-related
disorders in males: group (i) includes the most severely
affected males, group (ii) is a mitigation of group (i),
and group (iii) includes males with variable ID and faculta-
tive clinical features. Our detailed analysis of the impact of
mutations on CASK pre-mRNA splicing and protein
expression indicates a genotype-phenotype correlation: in-
activating CASK germline mutations are associated with
the most severe phenotype (MICPCH with severe epileptic
encephalopathy), while in the mosaic state these mutations
result in an attenuated phenotype (MICPCH) that can also
be caused by partly penetrant CASK mutations. CASK al-
terations leaving the protein intact, but with a reduced
functionality or a reduction in protein level, are found in
males with highly variable X-linked ID. We recommend
CASK testing in male patients with the combination of
DD/ID or epileptic encephalopathy, postnatal microcephaly
(< −3 SD) and pontocerebellar hypoplasia. Sequencing of
exons 22–27 may also be considered in patients with ID
and nystagmus.
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Additional file 1: Figure S1. Detection of a 150 kb de novo deletion at
Xp11.4 targeting CASK in patient 7 by array CGH. Below the ideogram of
the X chromosome, genomic copy numbers are shown along the X
chromosome (Agilent 180K array). In the lower part the genomic profiles
from individual 7 (upper line), his mother (middle line) and father (lower
line) at Xp11.4 is zoomed in showing the deletion within the CASK gene in
the patient (yellow shaded box, from 41,496,539 to 41,655,017 according to
hg19). This deletion is not present in the parents. Figure S2. Detection of a
duplication of 450-600 kb (chrX: 41,531,408-41,987,619; hg18) in patient 8
(Agilent 60K array). Duplicated probes are indicated in green on their genomic
position on the X chromosome. Probes with a normal copy number are indi-
cated in black. The lines represent the segmentation algorithm that was used
(CBS). Below the enlarged ideogram, the genes in the duplicated interval and
in the surrounding region are indicated in blue. Table S1. Primer sequences
and primer combinations for CASK transcript analysis in patients 1, 2, 5 and 8.
Table S2. FISH with two fosmid clones covering the mosaic CASK exon 3-9
deletion in patient 7. Table S3. Quantification of different CASK transcript
variants in patient 1.Competing interests
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